Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients

Pharmacogenomics

Volumn 13, Issue 10, 2012, Pages 1173-1191

  Cortejoso, Lucía ^a,b   López Fernández, Luis A ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

adverse reactions; cancer; colon; pharmacogenetics; rectum

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TEGAFUR; UFT;

ABCB1 GENE; ABDOMINAL PAIN; ADVERSE DRUG REACTION; AGRANULOCYTOSIS; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DPYD GENE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSGEUSIA; DYSPNEA; ELECTROCARDIOGRAM; EPISTAXIS; ERCC1 GENE; ERCC2 GENE; EXCISION REPAIR; FATIGUE; FEBRILE NEUTROPENIA; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GSTM1 GENE; GSTT1 GENE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOKALEMIA; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOCYTOPENIA; MTHFR GENE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHARMACOGENETICS; PIGMENTATION; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SMELLING DISORDER; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TUMOR GENE; TYMS GENE; UGT1A1 GENE; WEIGHT GAIN; XRCC1 GENE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84865342457     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.95     Document Type: Review

References (101)

1. Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann. Oncol. 22(2), 355-361 (2011).
2. Gonzalez-Haba E, Garcia MI, Cortejoso L et al. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 11(12), 1715-1723 (2010).
3. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol. 28(15), 2556-2564 (2010).
4. McLeod HL, Sargent DJ, Marsh S et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol. 28(20), 3227-3233 (2010).
5. Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol. 27(33), 5519-5528 (2009).
6. Fernandez-Rozadilla C, Cazier JB, Moreno V et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. doi: 10.1038/tpj.2012.2 (2012) (Epub ahead of print).
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
8. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J. Clin. Oncol. 23(20), 4553-4560 (2005). (Pubitemid 46196586)
9. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25(2 Suppl. 5), 4-12 (1998). (Pubitemid 28248696)
10. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol. 42(Suppl. 43), S31-S43 (1998).
11. Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit. Rev. Oncol. Hematol. 79(3), 224-250 (2011).
12. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138), 1407-1412 (1998). (Pubitemid 28510873)
13. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13), 905-914 (2000).
14. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21(5), 807-814 (2003). (Pubitemid 46606439)
15. Pfeiffer P, Mortensen JP, Bjerregaard B et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur. J. Cancer 42(16), 2738-2743 (2006). (Pubitemid 44596255)
16. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 15(2), 808-815 (1997). (Pubitemid 27074252)
17. Glimelius B, Sorbye H, Balteskard L et al. A randomized Phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann. Oncol. 19(5), 909-914 (2008). (Pubitemid 351627306)
18. El-Khoueiry AB, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 24(1), 50-55 (2006). (Pubitemid 43247274)
19. Kadoyama K, Miki I, Tamura T, Brown J, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int. J. Med. Sci. 9(1), 33-39 (2012).
20. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16(4), 215-237 (1989). (Pubitemid 19114713)
21. Ciccolini J, Mercier C, Evrard A et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28(5), 678-685 (2006). (Pubitemid 44564069)
22. Van Kuilenburg AB, Vreken P, Abeling NG et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104(1), 1-9 (1999). (Pubitemid 29134634)
23. Gross E, Ullrich T, Seck K et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum. Mutat. 22(6), 498 (2003).
24. Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9), 1321-1336 (2011).
25. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 5(6), 795-806 (2011).
26. Boisdron-Celle M, Remaud G, Traore S et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249(2), 271-282 (2007). (Pubitemid 46452935)
27. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res. 9(8), 3021-3028 (2003). (Pubitemid 36993262)
28. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10), 3455-3468 (2011).
29. Kleibl Z, Fidlerova J, Kleiblova P et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 56(4), 303-316 (2009).
30. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).
31. Aschele C, Debernardis D, Casazza S et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol. 17(6), 1760-1770 (1999). (Pubitemid 29269245)
32. Afzal S, Gusella M, Jensen SA et al. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. Pharmacogenomics 12(9), 1257-1267 (2011).
33. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol. 69(1), 58-66 (2010).
34. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J. Clin. Oncol. 25(10), 1247-1254 (2007). (Pubitemid 46640571)
35. Thomas F, Motsinger-Reif AA, Hoskins JM et al. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br. J. Cancer 105(11), 1654-1662 (2011).
36. Goekkurt E, Al-Batran SE, Hartmann JT et al. Pharmacogenetic analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J. Clin. Oncol. 27(17), 2863-2873 (2009).
37. Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J. Int. Med. Res. 38(3), 870-883 (2010).
38. Afzal S, Gusella M, Vainer B et al. Combinations of polymorphisms in genes involved in the 5-fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin. Cancer Res. 17(11), 3822-3829 (2011).
39. van der Put NM, Gabreels F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62(5), 1044-1051 (1998). (Pubitemid 28199004)
40. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J. 8(4), 256-267 (2008). (Pubitemid 352038305)
41. Sharma R, Hoskins JM, Rivory LP et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin. Cancer Res. 14(3), 817-825 (2008). (Pubitemid 351231165)
42. Gusella M, Frigo AC, Bolzonella C et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br. J. Cancer 100(10), 1549-1557 (2009).
43. Chua W, Goldstein D, Lee CK et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br. J. Cancer 101(6), 998-1004 (2009).
44. Glimelius B, Garmo H, Berglund A et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11(1), 61-71 (2011).
45. Taflin H, Wettergren Y, Odin E, Carlsson G, Derwinger K. Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer. Anticancer Res. 31(9), 3057-3062 (2011).
46. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14(6), 1797-1803 (2008). (Pubitemid 351469466)
47. Ueno H, Kaniwa N, Okusaka T et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br. J. Cancer 100(6), 870-873 (2009).
48. Caronia D, Martin M, Sastre J et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin. Cancer Res. 17(7), 2006-2013 (2011).
49. Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin. Pharmacol. Ther. 83(4), 589-594 (2008). (Pubitemid 351417063)
50. Hirose T, Fujita K, Nishimura K et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol. Rep. 24(2), 529-536 (2010).
51. Kim KP, Jang G, Hong YS et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br. J. Cancer 104(4), 605-612 (2011).
52. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30(6), 445-600 (1995).
53. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem. 272(15), 10004-10012 (1997). (Pubitemid 27171673)
54. Chen YC, Tzeng CH, Chen PM et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 101(2), 530-535 (2010).
55. Pare L, Marcuello E, Altes A et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br. J. Cancer 99(7), 1050-1055 (2008).
56. Kweekel DM, Koopman M, Antonini NF et al. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br. J. Cancer 99(8), 1316-1321 (2008).
57. Kweekel DM, Gelderblom H, Antonini NF et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur. J. Cancer 45(4), 572-578 (2009).
58. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 12(10), 3050-3056 (2006). (Pubitemid 43837350)
59. Inada M, Sato M, Morita S et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int. J. Clin. Pharmacol. Ther. 48(11), 729-734 (2010).
60. Agostini M, Pasetto LM, Pucciarelli S et al. Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs Aging 25(6), 531-539 (2008). (Pubitemid 351812260)
61. Chang PM, Tzeng CH, Chen PM et al. ERCC1 codon 118 C-T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 100(2), 278-283 (2009).
62. Lai JI, Tzeng CH, Chen PM et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 100(7), 1261-1266 (2009).
63. Duell EJ, Wiencke JK, Cheng TJ et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21(5), 965-971 (2000). (Pubitemid 30265141)
64. Wang Z, Xu B, Lin D et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 62(1), 99-104 (2008).
65. Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101(4), 847-854 (1998). (Pubitemid 28096082)
66. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun. 260(1), 199-202 (1999). (Pubitemid 29351807)
67. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62(3), 608-617 (2002). (Pubitemid 36329379)
68. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31(10), 687-699 (2001). (Pubitemid 33001093)
69. Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2(1), 43-47 (2002). (Pubitemid 34982202)
70. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91(4), 678-682 (2004). (Pubitemid 39141623)
71. Martinez-Balibrea E, Abad A, Martinez-Cardus A et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br. J. Cancer 103(4), 581-589 (2010).
72. Massacesi C, Terrazzino S, Marcucci F et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106(5), 1007-1016 (2006).
73. Rouits E, Charasson V, Petain A et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 99(8), 1239-1245 (2008).
74. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004). (Pubitemid 41103619)
75. Biason P, Masier S, Toffoli G. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J. Chemother. 20(2), 158-165 (2008). (Pubitemid 351797053)
76. Cecchin E, Innocenti F, D'Andrea M et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15), 2457-2465 (2009).
77. Cote JF, Kirzin S, Kramar A et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13(11), 3269-3275 (2007). (Pubitemid 46944912)
78. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br. J. Cancer 99(2), 275-282 (2008).
79. Liu CY, Chen PM, Chiou TJ et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112(9), 1932-1940 (2008).
80. Shulman K, Cohen I, Barnett-Griness O et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117(14), 3156-3162 (2011).
81. Toffoli G, Cecchin E, Corona G et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24(19), 3061-3068 (2006). (Pubitemid 46638941)
82. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007). (Pubitemid 47394168)
83. Schulz C, Heinemann V, Schalhorn A et al. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J. Gastroenterol. 15(40), 5058-5066 (2009).
84. Marcuello E, Paez D, Pare L et al. A genotype-directed Phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105(1), 53-57 (2011).
85. Innocenti F, Kroetz DL, Schuetz E et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27(16), 2604-2614 (2009).
86. Ferraldeschi R, Minchell LJ, Roberts SA et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics 10(5), 733-739 (2009).
87. Okuyama Y, Hazama S, Nozawa H et al. Prospective Phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J. Clin. Oncol. 41(4), 477-482 (2011).
88. Jada SR, Lim R, Wong CI et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421CA polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98(9), 1461-1467 (2007). (Pubitemid 47241771)
89. Carlini LE, Meropol NJ, Bever J et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11(3), 1226-1236 (2005). (Pubitemid 40175775)
90. Fujita K, Ando Y, Nagashima F et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother. Pharmacol. 60(4), 515-522 (2007). (Pubitemid 47084262)
91. Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24(15), 2237-2244 (2006).
92. Rhodes KE, Zhang W, Yang D et al. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab. Lett. 1(1), 23-30 (2007).
93. Sai K, Saito Y, Fukushima-Uesaka H et al. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother. Pharmacol. 62(3), 529-537 (2008).
94. van der Bol JM, Mathijssen RH, Creemers GJ et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res. 16(2), 736-742 (2010).
95. Hoskins JM, Marcuello E, Altes A et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin. Cancer Res. 14(6), 1788-1796 (2008). (Pubitemid 351469465)
96. Baas JM, Krens LL, Guchelaar HJ et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat. Rev. 38(5), 505-514 (2012).
97. Dahan L, Norguet E, Etienne-Grimaldi MC et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 11, 496 (2011).
98. Graziano F, Ruzzo A, Loupakis F et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 26(9), 1427-1434 (2008).
99. Kiyotani K, Uno S, Mushiroda T et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet. Genomics 22(4), 229-235 (2012).
100. Won HH, Lee J, Park JO et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118(11), 2828-2836 (2012).
101. Caussanel JP, Lévi F, Brienza S et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl Cancer Inst. 82(12), 1046-1050 (1990). (Pubitemid 20204976)